bimagrumab semaglutide combination trial nct suggests GLP-1 combo therapy cuts fat while preserving muscle in obesity A phase 2 clinical trial

Moreover, with heart disease being a significant concern for those dealing with insulin resistance, semaglutide's cardiovascular benefits cannot be overlooked

The metabolic shift Something fundamental changes around weeks 13 to 16 that goes beyond appetite suppression

Insured mortality and morbidity Insured groups and annuitants are likely to see somewhat lower mortality and morbidity reductions than the general population

Study of Semaglutide on Mental Health A study made in 2024, analyzing data from over 3,500 participants across multiple clinical trials found no increased risk of mental health issues among those using semaglutide for weight loss

GLP-1s and Birth Control A GLP-1 receptor agonist may reduce the effectiveness of oral contraceptives